China Universal Asset Management »

Allogene Therapeutics shares owned by China Universal Asset Management

Quarter-by-quarter ownership of Allogene Therapeutics (ALLO) shares owned by China Universal Asset Management from 13F filings

Historical chart of China Universal Asset Management investment in Allogene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Allogene Therapeutics held by China Universal Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allogene Therapeutics by China Universal Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $145k 32k 4.48
2023-12-31 $62k 20k 3.18
2023-09-30 $14k 4.3k 3.26
2023-06-30 $10k 1.9k 5.23
2023-03-31 $10k 2.0k 5.11
2022-12-31 $9.0k 1.5k 6.14
2022-09-30 $15k 1.3k 11.14

More positions owned by China Universal Asset Management

Microsoft Corp Common Stock (MSFT)
Nvidia Corp Common Stock (NVDA)
Amazon.com Common Stock (AMZN)
Meta Platforms Inc-class A Common Stock (META)
Vertex Pharmaceuticals Common Stock (VRTX)
Amgen Common Stock (AMGN)
Servicenow Common Stock (NOW)
Gilead Sciences Common Stock (GILD)
Regeneron Pharmaceuticals Common Stock (REGN)
Alphabet Inc-cl A Common Stock (GOOGL)
Adobe Common Stock (ADBE)
Broadcom Common Stock (AVGO)
Visa Inc-class A Shares Common Stock (V)
Apple Common Stock (AAPL)
Uber Technologies Common Stock (UBER)

View all positions for China Universal Asset Management

Top funds holding Allogene Therapeutics

Tpg Gp A
Vanguard Group
Jpmorgan Chase & Co
PRIMECAP Management Company
Citadel Advisors
Goldman Sachs Group
T. Rowe Price Associates
Two Sigma Investments
Millennium Management
Vida Ventures Advisors
Dimensional Fund Advisors
Two Sigma Advisers
Charles Schwab Investment Management
Caxton Associates
Nordea Investment Management Ab

View all funds holding Allogene Therapeutics